AstraZeneca ditches plan to build £450mn UK vaccine plant

Unlock the editor’s digest in free

FT editor Raula Khalaf selected his favorite stories in this weekly newsletter.

Prime Minister Sir Care Starmer’s government has been withdrawn from the plan to create a £ 450 million UK vaccine manufacturing plant after a large number of state investment for the Mirside project.

Officials have given a revised offer of financial assistance for the site this month, which was a significant amount of $ 40 million in last year, people with knowledge about this arrangement.

Labor government of Starmer sought last summer Reduce the amount of state assistance According to people who have briefed the matter, the project has provided about $ 90 million to $ 40 million.

“After a prolonged discussion with the government, we are no longer trying to invest our planned investment,” Astrogenka said in a statement on Friday. “The final offer compared to the previous government’s proposal has influenced this decision, including several reasons, including time and decrease.”

The existing spec site will continue to produce and supply the flu vaccine, the company said.

The decision is a push for Starmar’s government, a few days after Chancellor Rachel Rive’s Life Science Companies try to position the United Kingdom as a very interesting place for investment.

However, last year, a number of other arrangements, including his tax-procurement budget and higher minimum wages, have created a response from business leaders who warn the steps that these steps would make the UK less attractive to invest.

Former Conservative Chancellor Jeremy Hunt’s Pharmaceutical Group included up to £ 70 million as a grant for an existing development Astrogenca The people say the speech vaccine facilities, as well as $ 20 million with the research and development assistance of the UK Health Protection Agency.

Treasury did not immediately respond to any request for comment.

Astrazenca close people say it looks at other potential manufacturing sites.

According to the market capital, the largest UK company was “deeply frustrated” with the UK government, another man said that there was only one point of tension in the conflict of the future of drug prices and the future of life science.

In November, Astrogenka said it had planned to invest $ 3.5 billion in research and development and production In the United StatesThe world’s largest pharmaceutical market, which produces 44 percent of the company’s sale.

Astrgeneca Chief Executive Passcal Sorriot said at the time that the investment “reflects the attraction of the business environment with the quality of talent and innovation”.

The company is also planning a $ 1.5bn production facility in Singapore and promised to invest $ 560 million in Canada last week.

People who are knowledgeable about business say that his decision on Spec benefits will not have any effect on other investment in the UK.

In March, the then conservative government in the UK said that Astrogenka Spike would invest $ 450 million on research, development and production of new vaccines.

The Financial Times reported that the company was trying to secure up to $ 100 million with state assistance.